Market Research Logo

Celiac Disease - Pipeline Review, H2 2018

Celiac Disease - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H2 2018, provides an overview of the Celiac Disease (Gastro


Introduction
Global Markets Direct Report Coverage
Celiac Disease - Overview
Celiac Disease - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Celiac Disease - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Celiac Disease - Companies Involved in Therapeutics Development
Amgen Inc
Calypso Biotech SA
IB Pharmaceuticals Inc
ImmusanT Inc
Intrexon Corp
Takeda Pharmaceutical Co Ltd
Topas Therapeutics GmbH
Zedira GmbH
Celiac Disease - Drug Profiles
AG-017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMG-714 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMY-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVX-176 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNZ-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CALY-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DEN-181 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Agonize Aryl Hydrocarbon Receptor for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ERW-1041E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kuma-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kuma-062 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
larazotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
latiglutenase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Oncology and Tropical Spastic Paraparesis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nexvax-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nexvax-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Protein for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Peptides for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Celiac Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vedolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-1227 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZED-754 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Celiac Disease - Dormant Projects
Celiac Disease - Product Development Milestones
Featured News & Press Releases
May 24, 2018: ImmusanT CEO Leslie Williams to Discuss Immunology of Celiac Disease at 2018 BIO International Convention
May 21, 2018: ImmusanT Expands Management Team to Strengthen Financial Operations and Accelerate Clinical Development
May 17, 2018: Celiac Disease KOL and Management Meetings around the Digestive Disease Week (DDW) conference on Monday, June 4, 2018, in Washington, D.C.
May 15, 2018: ImmusanT Welcomes Ken Truitt as Chief Medical Officer
May 15, 2018: ImmusanT Welcomes Ken Truitt, M.D. as Chief Medical Officer
May 09, 2018: Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for the Digestive Disease Week 2018 Conference
Jan 08, 2018: Cour Pharmaceuticals Receives FDA Fast Track Designation For TIMP-GLIA
Jan 04, 2018: ImmusanT Provides Year-End Update and Outlines Goals for 2018
Nov 28, 2017: ImmusanT Data Shows Up-Dosing Substantially Increases Nexvax2 Dose Levels That Are Safe and Tolerable, Further Supports Phase II Studies
Oct 31, 2017: ImmusanT Presents Clinical Data Supporting Improved Dosing Strategy for Nexvax2 and Explaining Early Gluten-Related Clinical Effects in Celiac Disease
Oct 25, 2017: ImmusanT Announces Acceptance of Late Breaking Celiac Interleukin Data at United European Gastroenterology Week
Oct 12, 2017: ImmusanT to Present New Nexvax2 Dosing Data at United European Gastroenterology Week
Sep 13, 2017: Bioniz Therapeutics Presents Data Demonstrating the Synergistic Effects of Cytokines IL-15 and IL-21 in Celiac Disease Pathogenesis
Sep 11, 2017: ImmusanT Presents Data from Multiple Studies Supporting Continued Development of Nexvax2
Aug 29, 2017: ImmunogenX Announces Publication of New Latiglutenase Analyses in Digestive Disease & Science
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Celiac Disease, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Celiac Disease - Pipeline by Amgen Inc, H2 2018
Celiac Disease - Pipeline by Calypso Biotech SA, H2 2018
Celiac Disease - Pipeline by IB Pharmaceuticals Inc, H2 2018
Celiac Disease - Pipeline by ImmusanT Inc, H2 2018
Celiac Disease - Pipeline by Intrexon Corp, H2 2018
Celiac Disease - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2018
Celiac Disease - Pipeline by Topas Therapeutics GmbH, H2 2018
Celiac Disease - Pipeline by Zedira GmbH, H2 2018
Celiac Disease - Dormant Projects, H2 2018
List of Figures
Number of Products under Development for Celiac Disease, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report